Epithelial cancer in Fanconi anemia complementation group D2 (*Fancd2*) knockout mice

Scott Houghtaling,^{1,5} Cynthia Timmers,¹ Meenakshi Noll,¹ Milton J. Finegold,³ Stephen N. Jones,⁴ M. Stephen Meyn,² and Markus Grompe¹

¹Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon 97239, USA;

²Department of Molecular and Medical Genetics, University of Toronto, Toronto, Canada M5S 1A8; ³Department of Pathology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas 77030, USA; ⁴Department of Cell Biology, University of Massachusetts Medical School, North Worcester, Massachusetts 01605, USA

Fanconi anemia (FA) is a genetic disorder characterized by hypersensitivity to DNA damage, bone marrow failure, congenital defects, and cancer. To further investigate the *in vivo* function of the FA pathway, mice with a targeted deletion in the distally acting FA gene *Fancd2* were created. Similar to human FA patients and other FA mouse models, *Fancd2* mutant mice exhibited cellular sensitivity to DNA interstrand cross-links and germ cell loss. In addition, chromosome mispairing was seen in male meiosis. However, *Fancd2* mutant mice also displayed phenotypes not observed in other mice with disruptions of proximal FA genes. These include microphthalmia, perinatal lethality, and epithelial cancers, similar to mice with *Brca2/Fancd1* hypomorphic mutations. These additional phenotypes were not caused by defects in the ATM-mediated S-phase checkpoint, which was intact in primary *Fancd2* mutant fibroblasts. The phenotypic overlap between *Fancd2*-null and *Brca2/Fancd1* hypomorphic mice is consistent with a common function for both proteins in the same pathway, regulating genomic stability.

[**Keywords:** Fanconi anemia; cancer; *Fancd2*; *Brca2*; DNA repair; chromosome pairing]

Supplemental material is available at <http://www.genesdev.org>.

Received April 14, 2003; revised version accepted June 6, 2003.

Fanconi anemia (FA) is an autosomal recessive disorder characterized by cellular sensitivity to DNA damage, bone marrow failure, and predisposition to cancer (Fanconi 1967; D'Andrea and Grompe 2003). Patients may also have congenital malformations including short stature, small gonads, microphthalmia, and skeletal defects (Alter 1993). At least eight complementation groups exist (FA-A through FA-G, including D1 and D2; Joenje et al. 1997; Timmers et al. 2001), and the genes for seven of these have been identified (*FANCA*, *FANCC*, *FANCD2*, *FANCE*, *FANCF*, *FANCG*, and *BRCA2*; Strathdee et al. 1992; Lo Ten Foe et al. 1996; de Winter et al. 1998, 2000a,b; Timmers et al. 2001; Howlett et al. 2002).

The precise functions of the FA, BRCA1, and BRCA2 proteins remain unclear, but there is evidence for overlapping roles. *FANCA*, *FANCC*, *FANCE*, *FANCF*, and *FANCG* interact in a multisubunit nuclear complex (Kupfer et al. 1997; Garcia-Higuera et al. 1999; de Winter

et al. 2000c; Medhurst et al. 2001). Genes constituting this complex act epistatically as shown by the redundant phenotypes of *Fanca*, *Fancc*, *Fancg*, and *Fanca/Fancc* double knockout mice (Noll et al. 2002). FANCD2 acts downstream of the nuclear complex. After DNA damage (Garcia-Higuera et al. 2001) and during the S phase of the cell cycle (Taniguchi et al. 2002a), FANCD2 is monoubiquitinated at Lys 561 but not in cells lacking any member of the upstream FA complex (Garcia-Higuera et al. 2001). Monoubiquitination of FANCD2 is required for its colocalization with RAD51 and BRCA1 in nuclear foci. FANCD2 can also be phosphorylated at Ser 222 by ATM (ataxia telangiectasia mutated). This modification requires wild-type nibrin (Nakanishi et al. 2002) and has been reported to mediate the damage-induced arrest of DNA synthesis in SV40-transformed fibroblasts (Taniguchi et al. 2002b).

The identification of BRCA2 as an FA protein has suggested a potential function for the pathway. BRCA2 binds single-stranded DNA (Yang et al. 2002), interacts directly with RAD51 (Marmorstein et al. 1998), and modulates its activity (Davies et al. 2001). Cells lacking functional BRCA2 are deficient in homology-directed repair of DNA double-strand breaks (Moynahan et al.

⁵Corresponding author.

E-MAIL houghtal@ohsu.edu; FAX (503) 494-6886.

Article published online ahead of print. Article and publication date are at <http://www.genesdev.org/cgi/doi/10.1101/gad.1103403>.

2001b; Tutt et al. 2001], and therefore the FA/BRCA pathway may function to modulate DNA repair by homologous recombination.

Mouse genetics has been useful for investigating the function of the FA/BRCA pathway. Knockouts of *Fancc* (Chen et al. 1996; Whitney et al. 1996), *Fanca* (Cheng et al. 2000; Noll et al. 2002), and *Fancg* (Yang et al. 2001; Koomen et al. 2002) all share a defect in germ-cell development and demonstrate cellular sensitivity to agents that produce DNA interstrand cross-links (ICLs). In contrast to human FA patients, however, FA mice do not develop anemia and do not have skeletal defects; nor are they at an increased risk for developing cancer. Targeted deletions have also been generated for the murine homolog of *BRCA2*. Whereas homozygous null mutants lacking *Brca2* (Sharan et al. 1997) die at midgestation, mice homozygous for a truncating mutation at the C terminus of *Brca2* are viable and show some phenotypic overlap with *Fanca*, *Fancc*, and *Fancg* knockout mice (Connor et al. 1997; McAllister et al. 2002). Here, we report the phenotype of mice homozygous for a null allele of the *Fancd2* locus.

Results

Generation of *Fancd2* knockout mice

Murine *Fancd2* is highly homologous to human *FANCD2* and consists of 44 exons (GenBank accession no. BC042619). The targeting construct (Fig. 1A) was designed to delete exons 26 and 27 (220 bp) of the 44-exon gene and is predicted to disrupt the reading frame of the mRNA, resulting in a premature nonsense codon at 54 bp downstream of the exon 25 and exon 28 junction. Chimeric males were bred to generate *Fancd2* heterozygotes and crossed to produce *Fancd2* mutants and controls in the syngeneic 129S4, the congenic C57BL/6J, and a mixed 129S4, C57BL/6J strain background (Fig. 1C).

To confirm that the targeted allele of *Fancd2* was a null mutation, reverse transcriptase PCR (RT-PCR) was performed using mRNA generated from *Fancd2* mutant and wild-type testes. A product of the predicted size was amplified from wild-type testes, and a product lacking exons 26 and 27 of *Fancd2* was amplified from *Fancd2* mutant testes, indicating that some mRNA is

transcribed from the mutant allele (data not shown). We next performed Western blots on protein extract prepared from mouse bone marrow and testes and mouse embryonic fibroblasts (MEFs) using an N terminus-specific antibody [kindly provided by Alan D'Andrea (Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA); Fig. 1D,E; data not shown]. Both isoforms of *Fancd2* (*Fancd2*-S, 156 kD and *Fancd2*-L, 162 kD) were detectable in wild-type testes extract. Only *Fancd2*-S was observed in extract from *Fanca* mutant and *Fanca/c* double mutant testes. Full-length *Fancd2* was also observed in Western blots using protein extract from wild-type MEFs and wild-type bone marrow (Fig. 1E; data not shown). Importantly, no full-length *Fancd2* or any bands of the predicted truncated protein's molecular weight (~88 kD) were observed in protein extract from testes, bone marrow, or MEFs. Thus, we conclude that the targeted allele of *Fancd2* is a null mutation at the protein level.

Fancd2 knockouts display phenotypes similar to *Fanca*, *Fancc*, and *Fancg* knockouts

Upon gross examination, *Fancd2* mutants on the 129S4 background were indistinguishable from their littermates. However, *Fancd2*^{-/-} mice on the C57BL/6J background were smaller than controls, similar to *Fancc* mice (M. Buchwald, pers. comm.). Mutants were consistently smaller than controls at each data point analyzed (see Supplementary Fig. 1). At day 5, mutant males weighed 2.5 ± 0.7 g ($n = 9$), and nonmutant control males weighed 3.1 ± 0.4 g ($n = 23$; $p < 0.05$, t -test), indicating delayed development in utero. At day 40 (adulthood), mutant males weighed 18.3 ± 1.2 g ($n = 3$), and nonmutant control males weighed 21.2 ± 1.0 g ($n = 19$; $p < 0.01$, t -test). A similar result was found for female mutants and controls. We conclude that *Fancd2* mutant mice display a developmental delay in utero as well as postnatally.

Individual testes from adult (age 2–6 mo) *Fancd2* mutant and control animals on the 129S4 background were also examined. The average weight per testis from *Fancd2* mutants (23 ± 4 mg; $n = 20$) was smaller than that of controls (90 ± 19 mg; $n = 13$; $p < 0.001$, one-way ANOVA). Interestingly, the testicular weight of *Fancd2* mutants was also significantly reduced compared with

Figure 1. Targeted disruption of murine *Fancd2*^{-/-} gene. (A) Schematic of targeting vector, wild-type *Fancd2* locus, targeted allele with *neo-ura* cassette, and targeted allele without *neo-ura* cassette. Homologous integration of the targeting plasmid replaces *Fancd2* exons 26 and 27 with a *neo-ura* cassette flanked by *lox* sites. The binding site for the probe is indicated by a black bar. (B) Southern blot analysis using genomic DNA from targeted ES cell clones digested with *Xba*I. Homologous integration of the targeting plasmid eliminates an *Xba*I site in intron 26, resulting in a nontargeted band at 3.6 kb and a wild-type band at 8.3 kb. (C) PCR genotyping using genomic DNA from wild-type, heterozygous, and mutant tail as templates. Mutant *Fancd2* alleles with and without the *neo-ura* cassette are shown. The mutant band is 556 bp (with *neo-ura*) or 459 bp (without *neo-ura*). The wild-type band is 303 bp. (D) Western blot with anti-*Fancd2* antibody on protein lysate from *Fancd2* mutant, *Fanca/c* double mutant, wild-type, and *Fanca* mutant testes. *Fancd2*-S (155 kD) and *Fancd2*-L (162 kD) are visible in wild-type extracts. Only *Fancd2*-S is detectable in *Fanca/c* mutant and *Fanca* mutant extracts. No signal is detectable in *Fancd2* mutant extract. (E) Western blot with anti-*Fancd2* antibody on protein lysate from wild-type and *Fancd2* mutant MEFs either untreated or irradiated with 10 Gy. *Fancd2* (155/162 kD) is detected in wild-type extracts but absent from *Fancd2* mutant extracts. The absence of a band at 88 kD, corresponding to the predicted size of truncated *Fancd2*, is indicated.

Fanca (78 ± 13 mg; $n = 14$; $p < 0.001$, one-way ANOVA) and *Fancc* mutants (56 ± 15 mg; $n = 14$; $p < 0.001$, one-way ANOVA) on the same strain background (Noll et al. 2002). Despite the weight difference, histological exami-

nation of adult *Fancd2* mutant testes showed a similar mosaic pattern of normal and abnormal tubules. This characteristic pattern consists of apparently normal tubules, abnormal tubules that lack all germ cells, and ab-

normal tubules that contain germ cells but have increased numbers of apoptotic pachytene spermatocytes along with a relative paucity of diplotene spermatocytes and spermatids (Fig. 2A–D).

Ovaries from adult females were also abnormal and contained a markedly reduced number of developing follicles (data not shown.) Importantly, there was a lack of germ cells in testes of newborn *Fancd2* mutants (data

Figure 2. Germ-cell and meiotic pairing abnormalities in *Fancd2*^{-/-} mice. (A,B) H&E staining of testis sections from 7-week-old wild-type (A) or *Fancd2*^{-/-} (B) littermates. All stages of spermatogenesis are seen in the wild-type adult testes. *Fancd2*^{-/-} testes show a mosaic pattern of normal-appearing tubules (tubule 1), tubules with vacuolated Sertoli cell cytoplasm and no germ cells (tubule 2) and tubules with vacuolated Sertoli cell cytoplasm and decreased numbers of spermatocytes and spermatids (tubule 3). Magnification, 20×. (C,D) TUNEL staining of testes sections from 7-week-old wild-type (C) and *Fancd2*^{-/-} (D) littermates. Occasional cells were labeled in wild-type tubules near the basement membrane, whereas *Fancd2*^{-/-} testes contain tubules with multiple numbers of apoptotic spermatocytes. The nuclei of apoptotic cells are TUNEL-labeled with Cy3-dCTP and fluoresce red. Magnification, 20×. (E–H) Meiotic pairing abnormalities in *Fancd2*^{-/-} spermatocytes detected by indirect immunofluorescence staining for Scp3 (green) and Rad51 (red). (E) Zygotene wild-type nucleus. (F) Zygotene *Fancd2*^{-/-} nucleus with unusually long unpaired axial elements. (G) Late zygotene *Fancd2*^{-/-} nucleus with multiple synaptic abnormalities. (H) Pachytene *Fancd2*^{-/-} nucleus with unpaired (open arrowheads) and mispaired homologs (closed arrowheads). Magnification, 100×.

not shown), as previously also reported for *Fancc* mice (Whitney et al. 1996). This finding, together with the observed deficiency of spermatogonia in adult males (Fig. 2B), provides evidence that the FA pathway may be important for the survival of early germ cells. Alternatively, the phenotype might also be caused indirectly as a result of an inability to repair DNA damage that occurs constitutively.

The excess of apoptotic spermatocytes seen in some *Fancd2* tubules suggested that loss of *Fancd2* function may lead to aberrant germ-cell development during meiosis I. To follow meiotic events, we examined surface spreads of mouse spermatocytes using polyclonal antibodies against Rad51 and against Scp3, a component of the axial elements of unsynapsed chromosomes and of synaptonemal complexes that form between homologous chromosomes (Dobson et al. 1994). *Fancd2*^{-/-} mice display the same meiotic pairing abnormalities as those seen in other FA mice (S. Meyn, unpubl.). The earliest substages of meiotic prophase (leptonema and early zygonema) appear normal in *Fancd2*^{-/-} spermatocytes, as monitored by Scp3 and Rad51 staining. However, there was an increased frequency of synaptic abnormalities beginning in mid-zygonema. Synapsis between homologs is normally initiated while axial elements are still forming. As a result, unpaired axial elements in wild-type zygotene spermatocytes are typically short, with nearly full-length but unpaired axial elements uncommon (Fig. 2E). Unpaired axial elements in most zygotene *Fancd2*^{-/-} nuclei tended to be longer than normal (Fig. 2F), and some zygotene *Fancd2*^{-/-} nuclei contained multiple full-length axial elements that had aligned with their homologs but failed to synapse properly (Fig. 2G). The majority of *Fancd2*^{-/-} pachytene nuclei appeared to be normal. However, there was an excess of *Fancd2*^{-/-} pachytene nuclei with autosomal axial elements that had failed to synapse and/or with nonhomologs that had attempted to pair (Fig. 2H). These observations suggest that, although the FA pathway is not absolutely required for meiosis I, it acts to promote efficient and accurate pairing of homologs.

Fancd2 knockouts display phenotypes not observed in previous mouse models of FA

Fancd2 mutants also had phenotypes not previously observed in *Fanca*, *Fancc*, or *Fancg* knockout mice. Pups were born in near-expected Mendelian ratios from crosses of heterozygous 129S4 breeders; however, a significant deviation from the expected ratios was observed on the C57BL/6J background strain (data not shown). Only 16.5% (50/303), versus the expected 25%, of the pups present at the time of genotyping (postnatal day 5) were mutant ($p < 0.005$, χ^2 test). Although perinatal lethality has not been previously reported for FA knockout mice, it has been described in mice homozygous for a C terminus truncating mutation in *Brca2* in which an ~33% reduction of mutant animals was noted (McAllister et al. 2002). The lack of this phenotype in the 129S4 strain suggests the presence of a modifier locus in either

the 129S4 or C57BL/6J strain, which affects the penetrance of the perinatal lethality phenotype.

An increased incidence of eye abnormalities was observed for *Fancd2* mutants in the C57BL/6J background (Fig. 3), with 32 of 41 (78%) *Fancd2* mutants examined having microphthalmia. Consistent with previous reports, nonmutants in the C57BL/6J population also showed a low incidence (3.2%) of microphthalmia (Kal-

Figure 3. *Fancd2* mutants are predisposed to microphthalmia. (A) *Fancd2* mutants are smaller than wild-type controls at postnatal day 1. Microphthalmia is visible in *Fancd2* mutants. (B) Histology of eye from a wild-type control pup (postnatal day 1). Magnification, 50 $\times$. (C) Representative histology of eye from a *Fancd2*^{-/-} pup (postnatal day 1) shows a disorganized retina with lack of a distinct chamber or lens development. Magnification, 100 $\times$.

ter 1968). To determine if the phenotype was caused by altered expression of nearby genes, also referred to as position effects (Olson et al. 1996), and not the *Fancd2* mutation itself, the *neo-ura* cassette was removed by breeding to transgenic mice expressing Cre recombinase (see Materials and Methods). Consistent with our previous finding, 9 of 19 (47%) *Fancd2*^{-/-} pups with the allele lacking the *neo-ura* cassette but none of the controls had microphthalmia. This confirmed that *Fancd2* is capable of modifying the microphthalmia predisposition of C57BL/6J mice.

To determine whether *Fancd2* mutants are tumor-prone, a cohort of animals in the mixed and 129S4 backgrounds were monitored long-term. Animals were killed if abnormal growths were obvious or if they appeared otherwise unhealthy. A final sacrifice of all animals occurred at 18–24 mo for those in the mixed background and 7–17 mo for those in the 129S4 background. To date, 10 of 54 *Fancd2* mutants, 3 of 28 *Fancd2* heterozygote controls ($p > 0.05$), and 1 of 14 wild-type controls ($p > 0.05$) have developed adenomas ($p = 0.0385$ for *Fancd2* mutant vs. controls) or carcinomas ($p = 0.0328$ for *Fancd2* mutant vs. controls) at between 3 and 23 mo of age (Fig. 4A,B). Tumors occurred in multiple different epithelial cell types (summarized in Table 1). Paraffin-embedded sections of these tumors were stained with H&E (Fig. 4C–F) and classified by histological examination. Abnormal cell proliferation was confirmed by immunohistochemistry with an antibody to phosphorylated histone H3, a marker of mitosis (data not shown). The increased incidence of tumors in *Fancd2* mutants but not other FA mice demonstrates that complete loss of *Fancd2* function is necessary for the presentation of a cancer phenotype. The occurrence of hepatic adenomas in three of the heterozygous controls suggests that *Fancd2* heterozygotes may also be at an increased risk for carcinogenesis. However, these data are not statistically significant, and a larger study will be necessary to demonstrate this definitively. Importantly, although some controls developed hepatic adenomas, no carcinomas were observed in these mice.

Fancd2 and Fancc knockouts share a similar DNA damage response profile

FANCD2 acts downstream of the FA nuclear complex, and thus it may act as a convergence point between multiple upstream DNA damage response pathways (Garcia-Higuera et al. 2001). Furthermore, FANCD2 is phosphorylated by ATM following IR (Taniguchi et al. 2002b). These observations suggested that cells lacking FANCD2 might be more sensitive to DNA damage, particularly IR, than cells lacking FANCA, FANCC, or FANCG. To test this hypothesis, primary MEFs were prepared, and their sensitivity to various DNA-damaging agents was measured in cell growth assays. Cells were treated with increasing doses of mitomycin C (MMC), IR, or the photoactivated DNA cross-linking agent, 4'-hydroxymethyl-4,5', 8-trimethylpsoralen (HMT; Sigma) plus ultraviolet light (PUVA). As expected, *Fancd2* mu-

tant cells displayed a heightened sensitivity to MMC-induced DNA damage as compared with wild-type controls (Fig. 5A). *Fancd2* and *Fancc* mutant cells were equally sensitive to PUVA-induced ICLs (Fig. 5B). However, neither *Fancc* nor *Fancd2* mutant fibroblasts showed a differential sensitivity to IR when compared with wild-type controls (Fig. 5C).

To further investigate the role of *Fancd2* in the response to IR, we also exposed *Fancd2* mutants and controls to whole-body irradiation at doses of 9, 10, and 11 Gy (Fig. 5D; data not shown). We hypothesized that although neither *Fancd2* nor *Fancc* seems to function in response to IR in fibroblasts, a role for *Fancd2* may be revealed in whole animals. At a dose of 10 Gy, 11 of 14 controls survived, whereas only 3 of 14 *Fancd2* mutants survived ($p < 0.005$, Logrank test). No *Fancd2* mutants survived following a dose of 11 Gy, whereas 4 of 6 control animals survived. Thus, the LD₅₀ for *Fancd2* mutants was estimated to be 9.5 Gy compared with 11 Gy for nonmutant littermate controls (proportional difference ~1.15), which is identical to that previously reported for *Fancc* mutants (proportional difference of ~1.2; Noll et al. 2001). Although the *Fancd2* mutants had a moderate in vivo IR sensitivity similar to that of *Fancc* mutants, the lack of a differential sensitivity of *Fancd2* mutant MEFs or a major in vivo sensitivity of whole animals to irradiation supports the argument against a significant role for *Fancd2* in cellular responses to IR.

Primary Fancd2 mutant fibroblasts have an intact ATM-dependent S-phase checkpoint

Recent experiments have demonstrated that FANCD2 is phosphorylated at Ser 222 by the DNA damage signaling kinase, ATM. Using mutant cDNA constructs of human FANCD2, it was shown that this modification was necessary for the arrest of DNA synthesis after DNA damage, an ATM-dependent function (Taniguchi et al. 2002b). In addition, others have reported a defect in S-phase arrest in response to PUVA in multiple FA cell lines (Centurion et al. 2000; Sala-Trepat et al. 2000). These findings prompted the investigation of the status of the checkpoint in primary *Fancd2* mutant MEFs.

Primary (passage 2) *Fancd2* mutant and wild-type MEFs, and primary (passage 3) *Atm* mutant ear fibroblasts were treated with 10 Gy of IR, and their ability to inhibit DNA synthesis was measured. Whereas *Fancd2* mutant and wild-type cells inhibited DNA synthesis equally, *Atm* mutant cells did not (Fig. 5E). As a control, both *Fancd2* mutant and wild-type cells were then preincubated in 10 mM caffeine, an inhibitor of ATM (Sarkaria et al. 1999). Inhibition of ATM in these cells was capable of inducing a radioresistant DNA synthesis phenotype similar to that of *Atm* mutant cells (Fig. 5E).

Furthermore, both *Fancd2* mutant and wild-type cells were equally capable of inhibiting DNA synthesis following treatment with 0.5 ng/mL of PUVA, whereas *Atm* mutant cells were not and continued to incorporate DNA following damage (Fig. 5F). Together, these experi-

Figure 4. Histology of carcinomas and survival curves for *Fancd2* mutants and controls. Tumor-free (A; both adenoma and carcinoma) and carcinoma-free (B; only carcinoma) survival curves are shown for the combination of mixed and 129S4 populations. P values were determined by Logrank test. (C–F) H&E-stained paraffin-embedded sections of tumors from *Fancd2*^{−/−} animals. Arrows indicate mitotic cells with condensed chromatin. Magnification, 200×. (C) Ovarian adenocarcinoma with large acini lined by tall columnar cells having abundant eosinophilic cytoplasm and highly pleomorphic hyperchromatic nuclei (129S4, 3 mo). (D) Mammary adenocarcinoma in which large clusters of mitotically active and pleomorphic cells were found, ranging from columnar cells to nests of small, undifferentiated cells in clusters (mixed, 13 mo). (E) Lung adenocarcinoma of broncho-alveolar origin, with rows of columnar epithelial cells having a high nucleus-to-cytoplasm ratio lining septa, sometimes forming papillae or filling air spaces (129S4, 13 mo). (F) Hepatocellular carcinoma is multinodular and well differentiated. The neoplastic cells vary from being smaller than normal hepatocytes to 2×–3× larger (mixed background, 18 mo).

ments demonstrate that primary *Fancd2* mutant MEFs have an intact ATM-dependant S-phase checkpoint.

Expression and interaction of Rad51 and Brca2 is normal in Fancd2 mutants

Cells harboring mutations in genes implicated in control of homologous recombination repair of DNA damage,

including *BRCA1*, *BRCA2*, and *RAD51*, are sensitive to DNA interstrand cross-linking agents (Yu et al. 2000; Moynahan et al. 2001a). After treatment with ICLs, these cells show gross rearrangements involving nonhomologous chromosomes, a phenotype identical to cells from all FA complementation groups. *RAD51* functions in the process of homologous recombination (Baumann et al. 1996). *BRCA2* interacts directly with *RAD51*

Table 1. Increased incidence of tumors of epithelial cell origin in *Fancd2* mutant mice

Genotype	Background	Sex	Age at death	Tumor type
<i>Fancd2</i> ^{-/-}	Mixed	Female	14 mo	Ovarian adenoma
<i>Fancd2</i> ^{-/-}	Mixed	Male	15 mo	Hepatic adenoma
<i>Fancd2</i> ^{-/-}	Mixed	Male	19 mo	Hepatic adenoma ^a
<i>Fancd2</i> ^{-/-}	Mixed	Male	19 mo	Adenoma of fundic mucosa ^a
<i>Fancd2</i> ^{-/-}	Mixed	Male	18 mo	Gastric adenoma
<i>Fancd2</i> ^{-/-}	Mixed	Male	13 mo	Facial seborrheic keratosis
<i>Fancd2</i> ^{-/-}	Mixed	Female	13 mo	Mammary adenocarcinoma
<i>Fancd2</i> ^{-/-}	Mixed	Male	19 mo	B-cell lymphoma ^b
<i>Fancd2</i> ^{-/-}	Mixed	Male	19 mo	Hepatocellular carcinoma ^b
<i>Fancd2</i> ^{-/-}	Mixed	Male	19 mo	Bronchoalveolar carcinoma ^b
<i>Fancd2</i> ^{-/-}	Mixed	Male	19 mo	Bronchoalveolar carcinoma ^b
<i>Fancd2</i> ^{-/-}	Mixed	Male	18 mo	Hepatocellular carcinoma
<i>Fancd2</i> ^{-/-}	129S4	Male	13 mo	Lung adenocarcinoma
<i>Fancd2</i> ^{-/-}	129S4	Female	3 mo	Ovarian adenocarcinoma
<i>Fancd2</i> ^{-/+}	Mixed	Male	23 mo	Hepatic adenoma
<i>Fancd2</i> ^{-/+}	Mixed	Female	22 mo	Ovarian cystadenoma
<i>Fancd2</i> ^{-/+}	Mixed	Female	18 mo	Hepatic adenoma
Wild type	Mixed	Male	19 mo	Hepatic adenoma

^aHepatic adenoma and adenoma of fundic mucosa occurred in the same *Fancd2* mutant.

^bB-cell lymphoma and three primary tumors occurred in the same *Fancd2* mutant.

(Moynahan et al. 2001b), and cells lacking wild-type BRCA2 have increased levels of error-prone homology-directed repair of DNA double-strand breaks, suggesting that BRCA2 may function in error-free repair (Tutt et al. 2001). As *Fancd2* acts downstream of the FA complex, it was hypothesized that it may function to modulate the stability of Rad51 and Brca2 or their interaction.

To investigate this hypothesis, immunoblots with testicular lysates from *Fancd2* mutant, *Fancc* mutant, and control mice were prepared. Immunoblotting revealed no significant differences in the steady-state level of Rad51 (Fig. 6A). Immunoprecipitation of Brca2 from these lysates probed with the same Brca2 antibody also showed no significant differences in expression of Brca2 (data not shown).

We next asked whether *Fancd2* plays a role in modulating the interaction between Rad51 and BRCA2. Immunoprecipitation of Brca2 was performed on whole-cell lysates from *Fancd2* mutant, *Fancc* mutant, and wild-type mouse testes. An anti-Brca2 antibody but not control IgG was capable of immunoprecipitating Rad51 from whole-cell lysates of testis from *Fancd2* mutant, *Fancc* mutant, and wild-type animals (Fig. 6B). We conclude that the protein levels and interaction of Rad51 and Brca2 are normal in *Fancd2* mutant and *Fancc* mutant mice.

Finally, we performed immunocytochemistry experiments designed to examine whether Rad51 foci form normally in the nuclei of *Fancd2*-null fibroblasts following DNA damage (Fig. 6C). Primary wild-type and *Fancd2*^{-/-} MEFs were scored for the presence of Rad51 foci. An equal number of untreated wild-type (36%) and *Fancd2*^{-/-} (32%) MEFs contained >5 foci per nucleus. Similarly, no difference in the level of Rad51 foci was observed between wild-type (51%) and *Fancd2*^{-/-} (58%) MEFs 6 h after treatment with ionizing radiation. We

find that Rad51 foci formation is unaltered in *Fancd2*-null fibroblasts when compared with wild-type controls.

Discussion

The phenotype of human Fanconi anemia patients indicates that the FA pathway is important for normal embryonic development, the maintenance of genomic stability, and the preservation of several types of stem cells (Auerbach et al. 2001). The recent discovery that the breast cancer gene, *BRCA2*, is an FA gene (Howlett et al. 2002) has connected this rare disorder to a common form of cancer. Nonetheless, the precise function(s) of the FA/BRCA pathway remains unknown (D'Andrea and Grompe 2003). We and others have previously created strains of mice with targeted deletions of the murine *Fanca*, *Fancc*, and *Fancg* genes, all components of the FA nuclear complex. These mutants have very similar phenotypes (Chen et al. 1996; Whitney et al. 1996; Cheng et al. 2000; Yang et al. 2001; Koomen et al. 2002; Noll et al. 2002), supporting a model in which the components of the complex participate in a common function. To determine whether *Fancd2* participates only in this function in vivo or has additional roles, we generated a strain of mice with a null allele in this gene.

Earlier studies have suggested that FANCD2 may have unique roles that are distinct from the other FA proteins. First, it acts downstream of the FA nuclear complex and is the target of the monoubiquitination mediated by the complex (Garcia-Higuera et al. 2001; Timmers et al. 2001). Hence, the integrity of the FA nuclear complex is not perturbed in FA-D2 cells, unlike in other complementation groups (Garcia-Higuera et al. 1999; de Winter et al. 2000c). Second, FANCD2 is the only FA protein known to form nuclear foci after DNA damage and to colocalize with the repair proteins BRCA1 and RAD51

Figure 5. DNA damage sensitivity and S-phase checkpoint in *Fancc2*^{-/-} MEFs and mice. Primary MEFs were challenged with increasing doses of mitomycin C (A), 4'-hydroxymethyl-4,5',8-trimethylpsoralen (HMT) plus UVA (PUVA; B), or ionizing radiation (C). (●) Wild-type control MEFs; (○) *Fancc2* mutant MEFs; (▲) *Fancc* mutant MEFs. Experiments were performed in quadruplicate. Each data point represents the mean $\pm$ standard error of the mean (S.E.M.). (D) Survival curve of control (■, ●) and *Fancc2* mutant (□, ○) mice following a dose of 9 (solid line) and 10 (broken line) Gy of whole-body irradiation. (E,F) Primary *Fancc2*^{-/-} MEFs have an intact S-phase checkpoint. DNA synthesis was measured 30 min after treatment with 10 Gy of IR (E) or 0.5 ng/mL H-methoxy-triolsoralen (F) and is represented as the percentage of untreated controls. As a control, cells were also pretreated with 10 mM caffeine (caff). Experiments were performed in quintuplicate. Error bars indicate the S.E.M.

(Garcia-Higuera et al. 2001; Taniguchi et al. 2002a). Finally, FANCD2 is directly phosphorylated by ATM in response to IR but not in response to ICLs (Nakanishi et al. 2002; Taniguchi et al. 2002b). Other FA proteins are not known to be targets of the ATM kinase.

Despite these biochemical differences, human FA-D2 patients do not differ significantly clinically from FA patients belonging to other complementation groups (Timmers et al. 2001). However, FA-D2 is a rare complementation group, and all human patients reported to date have at least one mutant allele that could have some

residual function, and, therefore, the phenotype of a true *FANCD2*-null mutation remained uncertain. The *Fancc2* mutant mice reported here display all the features of previously reported strains of FA knockout mice, but also have important differences.

Fancc2, ionizing radiation, and the ATM signaling pathway

Ser 222 of human FANCD2 is phosphorylated by ATM in response to IR, and this posttranslational modification

Figure 6. Interaction of Rad51/Brca2 and Rad51 foci formation. (A) Whole-cell lysates from mouse testis of the indicated genotypes were separated by SDS-PAGE and probed with an antibody against Rad51. (B) Anti-Brca2 antibodies were used to immunoprecipitate protein complexes. Complexes were separated by SDS-PAGE and probed with an antibody against Rad51. "sn" indicates supernatant from immunocomplexes to compare bound versus unbound fraction. (C) Rad51 foci formation in wild-type and *Fancd2*^{-/-} MEFs either untreated (-IR) or following 12 Gy of ionizing radiation (+IR). Cell nuclei were counterstained with DAPI (blue).

has been correlated to increased IR sensitivity in immortalized fibroblasts (Taniguchi et al. 2002b). In addition, phosphorylation of Ser 222 was associated with radiation-induced arrest of DNA synthesis. Therefore, to test whether *Fancd2* played an important role in the response to IR, the survival of isogenic, primary cells from *Fancc* mutant and *Fancd2* mutant cells was compared. Interestingly, *Fancd2*-null cells were not differentially sensitive to IR or ICLs compared with *Fancc*-null cells. Furthermore, although mild hypersensitivity to IR was observed in vivo ($LD_{50} = \sim 9.5$ Gy), this sensitivity was also

not greater than that observed for *Fancc* mutant mice (Noll et al. 2001).

In addition, and in contrast to *Atm* mutants, *Fancd2*-deficient cells did not display radiation-resistant DNA synthesis. Therefore, in murine primary cells, *Fancd2* is not necessary for the ATM-mediated S-phase arrest following IR. Overall, the phenotype of *Fancd2* mutant mice is significantly different from that of *Atm*-null mice, which display marked radiation sensitivity, immune deficiency, and hematologic tumors (Xu et al. 1996). Together, our observations suggest that *Fancd2* does not play a significant role in ATM-mediated physiologic responses to IR. Perhaps human FANCD2 and murine *Fancd2* differ in this aspect of their function, although the proteins are highly homologous and Ser 222 is conserved between the species. Alternatively, *Fancd2* may play a role as a mediator of ATM function in only some specific circumstances, for example, T-antigen immortalized fibroblasts.

Novel phenotypes in *Fancd2* knockout mice

Although *Fancd2* mutant mice do not differ measurably from *Fancc* mutants in terms of their response to DNA damage, they have some features not seen in *Fancc*, *Fancc*, or *Fanccg* mutant animals. These phenotypes include microphthalmia, perinatal lethality, more severe hypogonadism, and tumor development. Normal function of the FA nuclear complex is necessary for the monoubiquitination of FANCD2 in response to DNA damage or DNA replication (Garcia-Higuera et al. 2001; Taniguchi et al. 2002a). Therefore, two basic models exist to explain the divergence of phenotypes between mutants in *Fancd2* and nuclear complex genes. First, nonubiquitinated *Fancd2* protein, as present in *Fancc*, *Fancc*, and *Fanccg* knockout mice, may have some residual activity in the function common to the FA pathway. In this model, knockouts of the nuclear complex genes would be similar to hypomorphic mutations of the *Fancd2* gene. The phenotypes would be the result of deficiency in the same biochemical function, but they would be more severe in *Fancd2* mutant mice. In the second model, FANCD2 is a multifunctional protein with a domain that functions in the FA pathway and other domains that mediate unrelated functions. The additional phenotypes of *Fancd2* mutants would then be caused by deficiency of these additional functions.

Most of the features observed in *Fancd2*-null mice can be interpreted as more severe manifestations of the qualitatively similar defects seen in other FA knockouts. This is most obvious with the germ-cell defects. Although testicular weight is clearly more affected in *Fancd2* mutant mice, the histology is similar to other FA models. Similarly, we have observed microphthalmia in the mutant offspring of some *Fancc* breeding pairs (M. Grompe, unpubl.), indicating that this is not a truly novel phenotype but a more complete manifestation of a defect common to all FA mice. The increased susceptibility of FA cells to apoptotic cell death after

DNA damage could provide a common explanation for the observed germ-cell deficiency, microphthalmia, small size, and perinatal lethality. In the case of these developmental defects, the cells would be responding to spontaneous DNA damage. Overall, the phenotype of *Fancd2* mutant mice does not convincingly establish the existence of additional functional domains in the *Fancd2* protein.

Fancd2, *Brca2*, and carcinomas

Although human patients with FA develop a variety of cancers, tumors have never been reported in the other FA knockout mice even when followed to very late ages. In contrast, it is well established that mice with a truncating mutation in *Brca2* are at an increased risk of a variety of neoplasms (Connor et al. 1997; McAllister et al. 2002). Interestingly, the tumor spectrum of the *Brca2* hypomorphic mice was comparable to that seen in *Fancd2* mutants (McAllister et al. 2002). In both cases, a predisposition toward epithelial cancers was seen, and the age of onset was similar. *Brca2* hypomorphic mice also have other similarities such as an FA-like germ-cell defect, small size, and perinatal lethality. Taken together, this extensive phenotypic overlap is consistent with the hypothesis that the C-terminal domain of *Brca2* functions in the same pathway as *Fancd2*.

Human BRCA2 is known to interact with and modulate the activity of RAD51, a central player in homologous recombination, and *Brca2* mutant cells are known to have defects in error-free recombination (Moynahan et al. 2001b; Tutt et al. 2001). Therefore, the identification of *Brca2* as an FA gene supports a role for the FA pathway in recombination DNA repair. This hypothesis is strengthened by the observation that chromosomes in the pachytene stage of meiosis mispair, as described here. One potential function for the FA pathway could be to control the interaction between Rad51 and *Brca2* and thereby modulate homologous recombination events at sites of DNA damage. However, Western blot analysis of *Fancd2* mutant tissues showed normal Rad51 levels as well as normal interaction of the *Brca2* and Rad51 proteins as determined by coimmunoprecipitation. Furthermore, Rad51 foci formation following DNA damage was normal in *Fancd2*^{-/-} MEFs. Thus, our data do not support a simple model in which the FA pathway controls the stability/rate of *Brca2*/Rad51 interaction.

In humans, heterozygosity for inactivating *BRCA2* germ-line mutations is associated with breast, ovarian, and pancreatic cancer, all tumors of epithelial origin. It is unclear at present why these tissues are particularly affected, but it is interesting to note that epithelial tumors in rodents have been associated with telomere shortening (Artandi et al. 2000; Chang et al. 2001). Human FA patients are known to display significantly shortened telomeres in hematopoietic cells (Leteurtre et al. 1999; Adelfalk et al. 2001; Brummendorf et al. 2001; Hanson et al. 2001), and it is therefore interesting to speculate that the FA/BRCA pathway could be involved in telomere maintenance in some tissues.

The high incidence of epithelial tumors observed in *Fancd2* mutants here also raises the issue whether *FANCD2* could be an important gene in some human epithelial cancers, especially of the breast and ovary. Importantly, some cases of familial ovarian cancer have been linked precisely to the region where *FANCD2* resides in the human genome (Sekine et al. 2001; Simsir et al. 2001; Zhang and Xu 2002). Future studies of human patients with these disorders will be needed to determine whether FA genes play a role in sporadic or inherited human cancers.

Materials and methods

Targeting vector design and generation of *Fancd2*-deficient mice

A λ phage library of mouse cDNA (Lambda FIX II-Stratagene) was screened with a 3' 3.0-kb RACE fragment of mouse *Fancd2* cDNA. DNA was purified from positive phage clones, and a 7.9-kb *Bam*HI fragment of genomic DNA was subcloned into the *Saccharomyces cerevisiae*/*Escherichia coli* shuttle vector, YCplac22-TK (Gietz and Sugino 1988), to generate YCplac22-TK + *Bam*HI fragment. This 7.9-kb fragment was further subcloned, sequenced, and found to contain exons 21–28 of the mouse *Fancd2* gene. The following primer pairs were used to amplify sequence flanking exons 26 and 27, and the PCR products were cloned into the plasmid pRAY-1 (Storck et al. 1996) to generate pRAY-1+ flanking arms: 5'-TCAGCCTCACATGGA GTTTAACG-3'/5'-GTGTGGACACTAACCTCACTCGC-3' and 5'-TTTCCTGTCTCATCTGCG-3'/5'-TGCAAAGAGAGAAA TGACTCAAG-3'. pRAY-1+ flanking arms and the YCplac22-TK + *Bam*HI fragment were cotransfected into yeast strain MW3317-21A (-trp, -ura) and selected in -ura/-trp dropout media. Clones were screened for a recombination event between the two plasmids that replaced mouse exons 26 and 27 with the *neo-ura* cassette from pRAY-1. YCplac22-TK + *Bam*HI (del exon26/27) was linearized and injected into 129S4 ES cells. gDNA was isolated from clones that were doubly resistant to G418 and gancyclovir, digested with *Xba*I, and Southern blotted using a 333-bp probe that binds 266–599 bp 3' of the *Bam*HI site marking the 3'-most end of genomic mouse sequence in the targeting vector (see Fig. 1B). The probe was amplified from total mouse genomic DNA using the following PCR primers pairs: 5'-GAGTTGTTCTTTTGTATGCCCGTC-3'/5'-GTCTTGTAT CTGCTTTCTCTGCG-3', and cloned into pCR-Blunt II-TOPO (Invitrogen). The probes were digested out with *Eco*RI. Four highly chimeric males were produced from blastocyst injections of correctly targeted ES cells.

Animal husbandry

Chimeric animals were crossed to C57BL/6J mice, and homozygous *Fancd2* knockout mice on a mixed 129S4, C57BL/6J background were generated. Founder animals were also backcrossed for six generations to pure C57BL/6J mice to generate a population of homozygous *Fancd2* knockout mice on the C57BL/6J background. A strain of congenic 129S4 *Fancd2* mutants was generated by breeding a germ-line chimera with 129S4 females. To generate *Fancd2* mutants that lacked the *neo-ura* knockout cassette, a *Fancd2* heterozygous male was crossed to a female mouse in a mixed C57BL/6J, DBA background containing the transgene encoding Cre recombinase driven by a testes-specific promoter [Jackson Labs strain #3466, B6;D2-TgN(Sycp1-Cre)4Min].

PCR genotyping

Fifty nanograms of gDNA was prepared from toes as previously described (Miller et al. 1988) and used as a template in PCR (Mullis and Faloona 1987) to genotype mice: a forward primer, MG968 (5'-TCAGCCTCACATGGAGTTTAACG-3') and two reverse primers, MG1007 (5'-AATTCGCCAATGACAAGACGC-3'; amplifies a mutant band of 556 bp) and MG1008 (5'-CAGGGATGAAAGGGTCTTACGC-3'; amplifies a wild-type band of 303 bp). The reaction conditions were 94°C for 3 min; 37 cycles of 94°C for 25 sec, 48°C for 25 sec, and 72°C for 35 sec; and a final extension at 72°C for 2 min. For detection of the *Fancd2* mutant allele lacking the *neo-ura* cassette, the same reaction was used but primer MG1007 was replaced with primer MG1280 (5'-GCTACACAGCATTGCCCATAAAG-3'; amplifies a mutant band of 459 bp).

Histology

Tissues fixed in 10% phosphate-buffered formalin for 24 h (pH 7.4) were dehydrated in 100% EtOH and embedded in paraffin wax at 58°C. Then 4- μ m sections were rehydrated and stained with hematoxylin and eosin (H&E).

Meiotic chromosome staining

Surface spreads of pachytene and diplotene spermatocytes from male mice between the ages of 16 and 35 d old were prepared as described by Peters et al. (1997). A polyclonal goat antibody to the mouse Scp3 protein was used to visualize axial elements and synaptonemal complexes in the meiotic preparations (Plug et al. 1997). The anti-Rad51 rabbit polyclonal antibody (Ab-1) was purchased from Oncogene Research Products. Antibody incubation and detection procedures were a modification of the protocol of Moens et al. (1987) as described by Keegan et al. (1996). Combinations of donkey anti-rabbit and donkey anti-goat IgG secondary antibodies conjugated to either FITC or TRITC were used for detection (Jackson ImmunoResearch Laboratories). All preparations were counterstained with 4',6'-diamino-2-phenylindole (DAPI, Sigma) and mounted in a DABCO (Sigma) antifade solution. The preparations were examined on a Zeiss Axioplan-2 microscope (63 $\times$ Plan Apochromat and 100 $\times$ Plan Apochromat oil-immersion objectives). Each fluorochrome (FITC, TRITC, and DAPI) image was captured separately as a 1344 $\times$ 1024-pixel, 12-bit grayscale source image via OpenLab software (Improvision) controlling a cooled-CCD camera (Hamamatsu Orca ER), and the separate grayscale images were cropped, 24-bit pseudocolored, and merged using Adobe Photoshop.

Cell growth assays

Primary (passage 2) mouse embryonic fibroblasts (MEFs) were prepared from pregnant mice at between 12 and 15 d postcoitus and seeded in quadruplicate at a density of 500 cells/well in 96-well plates. Cells were grown in Dulbecco's modified Eagle's medium (DMEM; GIBCO-BRL) supplemented with 15% fetal bovine serum (FBS; HyClone) and 1 $\times$ penicillin/streptomycin (GIBCO-BRL). Cells were treated with increasing doses of mitomycin C (Sigma; 0–640 ng/mL) or 4'-hydroxymethyl-4,5',8-trimethylpsoralen (HMT; Sigma) plus UVA (PUVA; 0–0.5 ng/mL), as previously described (Akkari et al. 2000). Ionizing radiation was administered at a dose of 145.9 rad/min from a ¹³⁷Cs source. Following treatment, cells were allowed to grow at 37°C for 5 d in 5% CO₂. Plates were frozen at –80°C. Total DNA was quantified using CyQuant (Molecular Probes) and compared

with untreated controls as an indication of cell growth as previously described (Cheng et al. 2000). Quantification of DNA using CyQuant was performed using a Fluorstar plate reader (B&L Systems) according to the manufacturer's instructions.

Radioresistant DNA synthesis (RDS) assay

The RDS assay was performed as previously described with modifications (Painter and Young 1980; Taniguchi et al. 2002b). Primary MEFs (wild-type and *Fancd2*, p2) or ear (*Atm*, p3) fibroblasts were seeded at a cell density of 75,000 per 60-mm dish. Cells were preincubated in media containing 10 nCi/mL thymidine [methyl-¹⁴C] (NEN Life Sciences, catalog #NEC568) for 24 h to control for total DNA content and then incubated for 24 h in nonradioactive media. Following DNA damage, cells were incubated at 37°C for 30 min with 5% CO₂ to allow arrest of DNA synthesis and then incubated in media containing 2.5 μ Ci/mL thymidine [methyl-³H] (NEN Life Sciences, catalog #NET027) for 3 h. Cells were postincubated at 37°C for 30 min with 5% CO₂ in nonradioactive media to remove unincorporated thymidine pools, washed three times in ice-cold phosphate-buffered saline (PBS), and fixed at room temperature in 90% methanol. Cells were scraped onto Whatman QF/C filters and air-dried for 10 min. Radioactivity was measured using a Beckman LS6500 scintillation counter. DNA synthesis is calculated from the ratio of ³H:¹⁴C cpm corrected for channel crossover and is represented as a percentage of untreated controls. Experiments were performed in quintuplet. The data shown are the mean $\pm$ standard error of the mean (S.E.M.).

Immunoblotting of Brca2, Rad51, and Fancd2

Preparation of whole-cell lysates: Testes from 4–6-week-old mice belonging to complementation groups A, C, D2, and control mice or MEFs were homogenized with an Eppendorf homogenizer containing 500 μ L of lysis buffer (1 $\times$ PBS, 1% Nonidet P-450, 0.5% sodium deoxycholate, and 0.2% SDS) including 20 μ g/mL phenylmethylsulfonyl fluoride, 1 μ g/mL leupeptin, and 1 μ g of aprotinin. The suspension was passed through a 27-gauge needle a few times to shear the DNA and centrifuged at 15,000g and 4°C for 20 min to remove the debris. The supernatant was stored at –80°C. Total protein from each of the samples was analyzed in triplicate using the Lowry assay (Lowry et al. 1951). For immunoprecipitation and Western blotting of Brca2, mouse monoclonal Brca2 (Ab-1) antibody (Oncogene Research Products) was used for the human cells, and a rabbit polyclonal anti-Brca2 (H-300) antibody was used for the mouse samples. Anti-Rad51 antibody (Santa Cruz Biotechnology, Inc.) was used on the mouse testicular samples for both immunoprecipitation (IP) and Western blotting.

Immunoblot analysis of Rad51: Testicular lysates were resolved on pre-cast Nupage 10%–12% Bis-Tris gels (Invitrogen, Life Technologies). Then 100 μ g of lysate was denatured by heating at 70°C for 10 min after the addition of an appropriate amount of 4 $\times$ Nupage sample buffer and 10 $\times$ reducing agent. The proteins were transferred to Immobilon-P Transfer membranes (Millipore Corporation), and Rad51 was detected using a 1:500 dilution of anti-Rad51 antibody (Santa Cruz Biotechnology, Inc.), a 1:2000 dilution of anti-rabbit secondary antibody (Amersham Life Science), and the ECL detection system (Amersham Life Science).

Immunoblot analysis of Fancd2: Testicular lysates were resolved on precast Nupage 3%–8% gradient gels (Invitrogen Life Technologies). MEF lysates were resolved on a 5% Tris-glycine gel. One-hundred micrograms of the lysates was denatured by heating at 70°C for 10 min after the addition of appropriate

amount of 4× Nupage sample buffer and 10× reducing agent. The proteins were transferred to Immobilon-P Transfer membranes (Millipore Corp.) and Fancd2 was detected using a 1:5000 (testes) or 1:1000 (MEFs) dilution of anti-FANCD2 polyclonal antibody and 1:10,000 dilution of anti-rabbit secondary antibody (Amersham Life Science) and the ECL system (Amersham Life Science).

Immunoprecipitation of Rad51 and Brca2 from testicular lysates

Preparation of Protein A Sepharose: The media (Amersham Life Science) was washed three times with the lysis buffer described above and centrifuged at 12,000g for 20 sec. The supernatant was discarded between washes. A 50% slurry was prepared by mixing equal volumes of media and lysis buffer, and was stored at 4°C.

Cell lysis: For Brca2, VU423 (Howlett et al. 2002) and HeLa cells were used as controls. The culture medium was removed, and the cells were washed twice with ice-cold PBS. The dishes were placed on ice, and the cells were collected with a cell scraper. Tissues were lysed in 100 μ L of lysis buffer and incubated on ice for 10–15 min with occasional shaking. The cells were further disrupted by passage through a 21-gauge needle. The lysates were centrifuged at 12,000g and 4°C for 10 min to remove particulate matter, and the supernatant was transferred to a fresh tube.

Immunoprecipitation: For immunoprecipitation, 1 mg (1 mL) of whole-cell or tissue extract was transferred to a 2-mL centrifuge tube. The lysate was precleared by adding 1 μ g of the appropriate normal mouse, rat, rabbit, or goat IgG together with 20 μ L of Protein A Sepharose conjugate. Incubation was done at 4°C for 1 h and pelleted by centrifugation at 2500 rpm and 4°C for 5 min. The precleared supernatant was transferred to a fresh Eppendorf tube.

Coupling of antigen to the antibody: The above supernatant was aliquoted to 500 μ L, and the respective primary antibodies (anti-Rad51, H-300 for mouse Brca2 and Ab-1 for human BRCA2) were added to a final concentration of 10 μ g/mL and mixed on a rotary shaker at 4°C for 1 h.

Precipitation of the immune complexes: Fifty microliters of Protein A Sepharose 4 Fast Flow suspension (50% slurry, described above) was added to the antigen–antibody complex and mixed on a rotary shaker at 4°C for 1 h. The complex was centrifuged at 12,000g for 20 sec, and both the pellet and the supernatant were saved to compare bound versus unbound protein. The pellet was washed three times with 1 mL of lysis buffer and once with wash buffer (50 mM Tris at pH 8.0).

Dissociation and analysis: Final pellets were suspended in 30 μ L of 4× Nupage sample buffer (Invitrogen) containing 1× DTT. The samples were heated to 95°C for 3 min and centrifuged at 12,000g for 20 sec to remove the beads. The supernatant was removed and analyzed by immunoblot as described above.

Rad51 foci formation immunocytochemistry

Primary wild-type and *Fancd2*^{−/−} MEFs were seeded on 18-mm coverslips and grown in DMEM + 15% FBS. Cells (untreated or treated with 12 Gy of ionizing radiation) were fixed 6 h after treatment with 4% paraformaldehyde at room temperature for 10 min and permeabilized with PBS + 0.5% Triton X-100 for 5 min. Cells were blocked in PBS-Tween 20 (0.25%) + 2% BSA at 4°C overnight. Anti-human RAD51 antibody (Oncogene) was used at a dilution of 1:1000 in PBS-Tween 20 (0.25%) + 2% BSA at room temperature for 1 h. Cells were washed four times for 5 min in PBS-Tween 20 (0.25%). Anti-rabbit-Cy3-conjugated sec-

ondary antibody (Upstate Biotechnology) was used at a dilution of 1:2000 in PBS-Tween 20 (0.25%) at room temperature for 1 h. Cells were washed four times for 5 min in PBS-Tween 20 (0.25%). Coverslips were mounted in a DAPI-containing antifade solution (Molecular Probes) and analyzed by fluorescence microscopy. Images were captured using Openlab software. The results are the mean of two independent experiments in which 200 cells were counted per experiment. Cells were scored positive if they contained >5 foci per nucleus.

Acknowledgments

We thank Alan D'Andrea for providing Fancd2 antibodies. This work was supported by NHLBI Program Project Grant 1P01HL48546 (M.G.).

The publication costs of this article were defrayed in part by payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 USC section 1734 solely to indicate this fact.

References

- Adelfalk, C., Lorenz, M., Serra, V., von Zglinicki, T., Hirsch-Kauffmann, M., and Schweiger, M. 2001. Accelerated telomere shortening in Fanconi anemia fibroblasts—A longitudinal study. *FEBS Lett.* **506**: 22–26.
- Akkari, Y.M., Bateman, R.L., Reifsteck, C.A., Olson, S.B., and Grompe, M. 2000. DNA replication is required to elicit cellular responses to psoralen-induced DNA interstrand cross-links. *Mol. Cell Biol.* **20**: 8283–8289.
- Alter, B.P. 1993. Fanconi's anaemia and its variability. *Br. J. Haematol.* **85**: 9–14.
- Artandi, S.E., Chang, S., Lee, S.L., Alson, S., Gottlieb, G.J., Chin, L., and DePinho, R.A. 2000. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. *Nature* **406**: 641–645.
- Auerbach, A.D., Buchwald, M., and Joenje, H. 2001. Fanconi anemia. In *The Metabolic and molecular basis of inherited disease* (ed. C.R. Scriver et al.), pp. 753–783. McGraw-Hill, New York.
- Baumann, P., Benson, F.E., and West, S.C. 1996. Human Rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro. *Cell* **87**: 757–766.
- Brummendorf, T.H., Rufer, N., Holyoake, T.L., Maciejewski, J., Barnett, M.J., Eaves, C.J., Eaves, A.C., Young, N., and Lansdorp, P.M. 2001. Telomere length dynamics in normal individuals and in patients with hematopoietic stem cell-associated disorders. *Ann. NY Acad. Sci.* **938**: 293–304.
- Centurion, S.A., Kuo, H.R., and Lambert, W.C. 2000. Damage-resistant DNA synthesis in Fanconi anemia cells treated with a DNA cross-linking agent. *Exp. Cell Res.* **260**: 216–221.
- Chang, S., Khoo, C., and DePinho, R.A. 2001. Modeling chromosomal instability and epithelial carcinogenesis in the telomerase-deficient mouse. *Semin. Cancer Biol.* **11**: 227–239.
- Chen, M., Tomkins, D.J., Auerbach, W., McKerlie, C., Youssoufian, H., Liu, L., Gan, O., Carreau, M., Auerbach, A., Groves, T., et al. 1996. Inactivation of Fac in mice produces inducible chromosomal instability and reduced fertility reminiscent of Fanconi anaemia. *Nat. Genet.* **12**: 448–451.
- Cheng, N.C., van de Vrugt, H.J., van der Valk, M.A., Oostra, A.B., Krimpenfort, P., de Vries, Y., Joenje, H., Berns, A., and Arwert, F. 2000. Mice with a targeted disruption of the Fanconi anemia homolog Fanca. *Hum. Mol. Genet.* **9**: 1805–1811.

- Connor, F., Bertwistle, D., Mee, P.J., Ross, G.M., Swift, S., Grigorieva, E., Tybulewicz, V.L., and Ashworth, A. 1997. Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation. *Nat. Genet.* **17**: 423–430.
- D'Andrea, A.D. and Grompe, M. 2003. The Fanconi anaemia/BRCA pathway. *Nat. Rev. Cancer* **3**: 23–34.
- Davies, A.A., Masson, J.Y., McIlwraith, M.J., Stasiak, A.Z., Stasiak, A., Venkitaraman, A.R., and West, S.C. 2001. Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. *Mol. Cell* **7**: 273–282.
- de Winter, J.P., Waisfisz, Q., Rooimans, M.A., van Berkel, C.G., Bosnoyan-Collins, L., Alon, N., Carreau, M., Bender, O., Demuth, I., Schindler, D., et al. 1998. The Fanconi anaemia group G gene FANCG is identical with XRCC9. *Nat. Genet.* **20**: 281–283.
- de Winter, J.P., Leveille, F., van Berkel, C.G., Rooimans, M.A., van Der Weel, L., Steltenpool, J., Demuth, I., Morgan, N.V., Alon, N., Bosnoyan-Collins, L., et al. 2000a. Isolation of a cDNA representing the Fanconi anemia complementation group E gene. *Am. J. Hum. Genet.* **67**: 1306–1308.
- de Winter, J.P., Rooimans, M.A., van Der Weel, L., van Berkel, C.G., Alon, N., Bosnoyan-Collins, L., de Groot, J., Zhi, Y., Waisfisz, Q., Pronk, J.C., et al. 2000b. The Fanconi anaemia gene FANCF encodes a novel protein with homology to ROM. *Nat. Genet.* **24**: 15–16.
- de Winter, J.P., van der Weel, L., de Groot, J., Stone, S., Waisfisz, Q., Arwert, F., Scheper, R.J., Kruij, F.A., Hoatlin, M.E., and Joenje, H. 2000c. The Fanconi anemia protein FANCF forms a nuclear complex with FANCA, FANCC and FANCG. *Hum. Mol. Genet.* **9**: 2665–2674.
- Dobson, M.J., Pearlman, R.E., Karaiskakis, A., Spyropoulos, B., and Moens, P.B. 1994. Synaptonemal complex proteins: Occurrence, epitope mapping and chromosome disjunction. *J. Cell Sci.* **107** (Pt 10): 2749–2760.
- Fanconi, G. 1967. Familial constitutional panmyelocytopenia, Fanconi's anemia (F.A.). I. Clinical aspects. *Semin. Hematol.* **4**: 233–240.
- Garcia-Higuera, I., Kuang, Y., Naf, D., Wasik, J., and D'Andrea, A.D. 1999. Fanconi anemia proteins FANCA, FANCC, and FANCG/XRCC9 interact in a functional nuclear complex. *Mol. Cell. Biol.* **19**: 4866–4873.
- Garcia-Higuera, I., Taniguchi, T., Ganesan, S., Meyn, M.S., Timmers, C., Hejna, J., Grompe, M., and D'Andrea, A.D. 2001. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. *Mol. Cell* **7**: 249–262.
- Gietz, R.D. and Sugino, A. 1988. New yeast-*Escherichia coli* shuttle vectors constructed with in vitro mutagenized yeast genes lacking six-base pair restriction sites. *Gene* **74**: 527–534.
- Hanson, H., Mathew, C.J., Docherty, Z., and Mackie Ogilvie, C. 2001. Telomere shortening in Fanconi anaemia demonstrated by a direct FISH approach. *Cytogenet. Cell Genet.* **93**: 203–206.
- Howlett, N.G., Taniguchi, T., Olson, S., Cox, B., Waisfisz, Q., De Die-Smulders, C., Persky, N., Grompe, M., Joenje, H., Pals, G., et al. 2002. Biallelic inactivation of BRCA2 in Fanconi anemia. *Science* **297**: 606–609.
- Joenje, H., Oostra, A.B., Wijker, M., di Summa, F.M., van Berkel, C.G., Rooimans, M.A., Ebell, W., van Weel, M., Pronk, J.C., Buchwald, M., et al. 1997. Evidence for at least eight Fanconi anemia genes. *Am. J. Hum. Genet.* **61**: 940–944.
- Kalter, H. 1968. Sporadic congenital malformations of newborn inbred mice. *Teratology* **1**: 193–199.
- Keegan, K.S., Holtzman, D.A., Plug, A.W., Christenson, E.R., Brainerd, E.E., Flaggs, G., Bentley, N.J., Taylor, E.M., Meyn, M.S., Moss, S.B., et al. 1996. The Atr and Atm protein kinases associate with different sites along meiotically pairing chromosomes. *Genes & Dev.* **10**: 2423–2437.
- Koomen, M., Cheng, N.C., van de Vrugt, H.J., Godthelp, B.C., van der Valk, M.A., Oostra, A.B., Zdzienicka, M.Z., Joenje, H., and Arwert, F. 2002. Reduced fertility and hypersensitivity to mitomycin C characterize Fancg/Xrcc9 null mice. *Hum. Mol. Genet.* **11**: 273–281.
- Kupfer, G.M., Naf, D., Suliman, A., Pulsipher, M., and D'Andrea, A.D. 1997. The Fanconi anaemia proteins, FAA and FAC, interact to form a nuclear complex. *Nat. Genet.* **17**: 487–490.
- Leteurtre, F., Li, X., Guardiola, P., Le Roux, G., Sergere, J.C., Richard, P., Carosella, E.D., and Gluckman, E. 1999. Accelerated telomere shortening and telomerase activation in Fanconi's anaemia. *Br. J. Haematol.* **105**: 883–893.
- Lo Ten Foe, J.R., Rooimans, M.A., Bosnoyan-Collins, L., Alon, N., Wijker, M., Parker, L., Lightfoot, J., Carreau, M., Callen, D.F., Savoia, A., et al. 1996. Expression cloning of a cDNA for the major Fanconi anaemia gene, FAA. *Nat. Genet.* **14**: 320–323.
- Lowry, O.H., Rosenbrough, N.J., Farr, A.L., and Randall, R.J. 1951. Protein measurement with the Folin phenol reagent. *J. Biol. Chem.* **193**: 265–275.
- Marmorstein, L.Y., Ouchi, T., and Aaronson, S.A. 1998. The BRCA2 gene product functionally interacts with p53 and RAD51. *Proc. Natl. Acad. Sci.* **95**: 13869–13874.
- McAllister, K.A., Bennett, L.M., Houle, C.D., Ward, T., Malphurs, J., Collins, N.K., Cachafeiro, C., Haseman, J., Goulding, E.H., Bunch, D., et al. 2002. Cancer susceptibility of mice with a homozygous deletion in the COOH-terminal domain of the Brca2 gene. *Cancer Res.* **62**: 990–994.
- Medhurst, A.L., Huber, P.A., Waisfisz, Q., de Winter, J.P., and Mathew, C.G. 2001. Direct interactions of the five known Fanconi anaemia proteins suggest a common functional pathway. *Hum. Mol. Genet.* **10**: 423–429.
- Miller, S.A., Dykes, D.D., and Polesky, H.F. 1988. A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acids Res.* **16**: 1215.
- Moens, P.B., Heyting, C., Dietrich, A.J., van Raamsdonk, W., and Chen, Q. 1987. Synaptonemal complex antigen location and conservation. *J. Cell Biol.* **105**: 93–103.
- Moynahan, M.E., Cui, T.Y., and Jasin, M. 2001a. Homology-directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. *Cancer Res.* **61**: 4842–4850.
- Moynahan, M.E., Pierce, A.J., and Jasin, M. 2001b. BRCA2 is required for homology-directed repair of chromosomal breaks. *Mol. Cell* **7**: 263–272.
- Mullis, K.B. and Faloona, F.A. 1987. Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. *Methods Enzymol.* **155**: 335–350.
- Nakanishi, K., Taniguchi, T., Ranganathan, V., New, H.V., Moreau, L.A., Stotsky, M., Mathew, C.G., Kastan, M.B., Weaver, D.T., and D'Andrea, A.D. 2002. Interaction of FANCD2 and NBS1 in the DNA damage response. *Nat. Cell Biol.* **4**: 913–920.
- Noll, M., Bateman, R.L., D'Andrea, A.D., and Grompe, M. 2001. Preclinical protocol for in vivo selection of hematopoietic stem cells corrected by gene therapy in Fanconi anemia group C. *Mol. Ther.* **3**: 14–23.
- Noll, M., Battaile, K.P., Bateman, R., Lax, T.P., Rathbun, K., Reifsteck, C., Bagby, G., Finegold, M., Olson, S., and Grompe, M. 2002. Fanconi anemia group A and C double-mutant mice. Functional evidence for a multi-protein Fanconi anemia complex. *Exp. Hematol.* **30**: 679–688.
- Olson, E.N., Arnold, H.H., Rigby, P.W., and Wold, B.J. 1996.

- Know your neighbors: Three phenotypes in null mutants of the myogenic bHLH gene MRF4. *Cell* **85**: 1–4.
- Painter, R.B. and Young, B.R. 1980. Radiosensitivity in ataxia-telangiectasia: A new explanation. *Proc. Natl. Acad. Sci.* **77**: 7315–7317.
- Peters, A.H., Plug, A.W., van Vugt, M.J., and de Boer, P. 1997. A drying-down technique for the spreading of mammalian meiocytes from the male and female germline. *Chromosome Res.* **5**: 66–68.
- Plug, A.W., Clairmont, C.A., Sapi, E., Ashley, T., and Sweasy, J.B. 1997. Evidence for a role for DNA polymerase beta in mammalian meiosis. *Proc. Natl. Acad. Sci.* **94**: 1327–1331.
- Sala-Trepat, M., Rouillard, D., Escarceller, M., Laquerbe, A., Moustacchi, E., and Papadopoulos, D. 2000. Arrest of S-phase progression is impaired in Fanconi anemia cells. *Exp. Cell Res.* **260**: 208–215.
- Sarkaria, J.N., Busby, E.C., Tibbetts, R.S., Roos, P., Taya, Y., Karnitz, L.M., and Abraham, R.T. 1999. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. *Cancer Res.* **59**: 4375–4382.
- Sekine, M., Nagata, H., Tsuji, S., Hirai, Y., Fujimoto, S., Hatae, M., Kobayashi, I., Fujii, T., Nagata, I., Ushijima, K., et al. 2001. Localization of a novel susceptibility gene for familial ovarian cancer to chromosome 3p22-p25. *Hum. Mol. Genet.* **10**: 1421–1429.
- Sharan, S.K., Morimatsu, M., Albrecht, U., Lim, D.S., Regel, E., Dinh, C., Sands, A., Eichele, G., Hasty, P., and Bradley, A. 1997. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. *Nature* **386**: 804–810.
- Simsir, A., Palacios, D., Linehan, W.M., Merino, M.J., and Abati, A. 2001. Detection of loss of heterozygosity at chromosome 3p25-26 in primary and metastatic ovarian clear-cell carcinoma: Utilization of microdissection and polymerase chain reaction in archival tissues. *Diagn. Cytopathol.* **24**: 328–332.
- Storck, T., Kruth, U., Kolhekar, R., Sprengel, R., and Seeburg, P.H. 1996. Rapid construction in yeast of complex targeting vectors for gene manipulation in the mouse. *Nucleic Acids Res.* **24**: 4594–4596.
- Strathdee, C.A., Gavish, H., Shannon, W.R., and Buchwald, M. 1992. Cloning of cDNAs for Fanconi's anaemia by functional complementation. *Nature* **356**: 763–767.
- Taniguchi, T., Garcia-Higuera, I., Andreassen, P.R., Gregory, R.C., Grompe, M., and D'Andrea, A.D. 2002a. S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. *Blood* **100**: 2414–2420.
- Taniguchi, T., Garcia-Higuera, I., Xu, B., Andreassen, P.R., Gregory, R.C., Kim, S.T., Lane, W.S., Kastan, M.B., and D'Andrea, A.D. 2002b. Convergence of the Fanconi anemia and ataxia telangiectasia signaling pathways. *Cell* **109**: 459–472.
- Timmers, C., Taniguchi, T., Hejna, J., Reifsteck, C., Lucas, L., Bruun, D., Thayer, M., Cox, B., Olson, S., D'Andrea, A.D., et al. 2001. Positional cloning of a novel Fanconi anemia gene, FANCD2. *Mol. Cell* **7**: 241–248.
- Tutt, A., Bertwistle, D., Valentine, J., Gabriel, A., Swift, S., Ross, G., Griffin, C., Thacker, J., and Ashworth, A. 2001. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. *EMBO J.* **20**: 4704–4716.
- Whitney, M.A., Royle, G., Low, M.J., Kelly, M.A., Axthelm, M.K., Reifsteck, C., Olson, S., Braun, R.E., Heinrich, M.C., Rathbun, R.K., et al. 1996. Germ cell defects and hematopoietic hypersensitivity to γ -interferon in mice with a targeted disruption of the Fanconi anemia C gene. *Blood* **88**: 49–58.
- Xu, Y., Ashley, T., Brainerd, E.E., Bronson, R.T., Meyn, M.S., and Baltimore, D. 1996. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. *Genes & Dev.* **10**: 2411–2422.
- Yang, H., Jeffrey, P.D., Miller, J., Kinnucan, E., Sun, Y., Thoma, N.H., Zheng, N., Chen, P.L., Lee, W.H., and Pavletich, N.P. 2002. BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. *Science* **297**: 1837–1848.
- Yang, Y., Kuang, Y., De Oca, R.M., Hays, T., Moreau, L., Lu, N., Seed, B., and D'Andrea, A.D. 2001. Targeted disruption of the murine Fanconi anemia gene, *Fancg/Xrcc9*. *Blood* **98**: 3435–3440.
- Yu, V.P., Koehler, M., Steinlein, C., Schmid, M., Hanakahi, L.A., van Gool, A.J., West, S.C., and Venkitaraman, A.R. 2000. Gross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation. *Genes & Dev.* **14**: 1400–1406.
- Zhang, G.L. and Xu, K.L. 2002. Loss of heterozygosity at chromosome 3p in epithelial ovarian cancer in China. *Int. J. Gynecol. Cancer* **12**: 198–201.

Epithelial cancer in Fanconi anemia complementation group D2 (*Fancd2*) knockout mice

Scott Houghtaling, Cynthia Timmers, Meenakshi Noll, et al.

Genes Dev. 2003, **17**:

Access the most recent version at doi:[10.1101/gad.1103403](https://doi.org/10.1101/gad.1103403)

Supplemental Material

<http://genesdev.cshlp.org/content/suppl/2003/07/31/1103403.DC1>

References

This article cites 64 articles, 21 of which can be accessed free at:
<http://genesdev.cshlp.org/content/17/16/2021.full.html#ref-list-1>

License

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).